{"nct_id":"NCT02319031","title":"Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis","status":"COMPLETED","status_verified_date":"2016-12","start_date":"2015-02","start_date_type":null,"primary_completion_date":"2015-10","primary_completion_date_type":"ACTUAL","completion_date":"2015-12","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["BMY"]}